Yi Lin, Professor at Mayo Clinic Comprehensive Cancer Center, shared a post on X:
“Now delving into bispecific antibodies therapies in multiple myeloma at iwCART25.
We have 3 antigen targets, dual & triple targets in clinic & trials. How best to optimize their use?
Rakesh Popat starts with Cevostamab data.”